Bellus Medical Raises the Standard in Microneedling Industry by Receiving ISO 13485:2016 Certification

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Bellus Medical, (medical aesthetics products and devices), recently earned the ISO 13485:2016 certification. ISO 13485:2016 specifies requirements for a quality management system where an organization needs to demonstrate its ability to provide medical devices and related services that consistently meet customer and applicable regulatory requirements. This certification has been established by the International Organization for Standardization (ISO), the largest developer and publisher of international standards. These standards ensure Bellus Medical meets world-class specifications for products, services and systems, to ensure quality, safety and efficiency.

Joe Proctor, Bellus Medical President and CEO, “The ISO 13485:2016 certification proves the strength of our organization, demonstrates our commitment to quality, and builds our customers’ confidence as their trusted partner.  He went on to say,  “I’m proud to recognize this significant milestone for our company, making Bellus Medical the only microneedling provider to meet the ISO 13485:2016 standards.”

Certification requirements

  • Documenting policies for record controls, internal auditing procedures, non-conformance controls, preventative and corrective actions, process and design controls, record retention, accountability and traceability.
  • Risk management must be thoroughly documented and conducted throughout a product’s entire lifecycle, from initial concept to delivery and post-delivery.

Benefits of ISO 13485:2016 certification

  • Access to international markets. National regulatory authorities require or strongly prefer that manufacturers marketing medical products in their countries have a third-party audited and certified management system in place. Investing in such a system speeds access into those countries that require it, and expedites market entry into the others.
  • Reduced cost of sales. Compliance reduces operational costs by improving efficiency and highlighting inefficient processes.
  • Improved customer satisfaction. Consistent delivery of high-quality products increases customer satisfaction, and positions Bellus Medical as a trusted partner.
  • Enhanced Trust. Demonstration of the executive management’s involvement in the dedication to the company’s quality system is required to obtain certification. This shows that Bellus Medical is focused on quality at every level of the organization…product, people and processes.

“This certification is a tangible demonstration of Bellus’ ability to provide medical devices and related services that consistently meet customer and applicable regulatory requirements with an industry-leading speed to market,” adds Dr. Thomas Hitchcock, Vice President of Medical and Clinical Affairs. “It also shows that we are able to secure and maintain global business because the standard is harmonized with most international regulatory agencies.”

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles